Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

The impact of frailty on real world outcomes for multiple myeloma patients in England – a cohort study from the uncover study group and ukmra frailty group.

Thea Chandler, Indrani Karpha, Nurunnahar Akter, Temitope Erinfolami, Hanhua Liu, Brogan Johnston, Yeong Lim, Nagesh Kalakonda, Gillian Brearton, Sally Moore, Hira Mian, Frances Seymour, Christopher Parrish, Charlotte Pawlyn, Catrin Tudur Smith, Andrew Pettitt, Gordon Cook

Blood (2025) 146 (Supplement 1): 2792.

https://doi.org/10.1182/blood-2025-2792

Published: 2025

Journal Articles

Respiratory syncytial virus (RSV) infection in adults with blood cancer: An England-wide population study

Yeong Jer Lim, Temitope Erinfolami, Nurunnahar Akter, Toyyib Abdulkareem, Andrew Ross, Brogan Johnston, Rebecca Lenihan, Lance Turtle, Muhammad Saif, Hanhua Liu, Mark Bishton, Nagesh Kalakonda, Indrani Karpha, Catrin Tudur Smith, Andrew Pettitt

Blood (2025) 146 (Supplement 1): 6402.

https://doi.org/10.1182/blood-2025-6402

Published: 2025

Journal Articles

Real world epidemiological trends in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), England 2014-2021: Preliminary data from the uncover Study group

Indrani Karpha, Nurunnahar Akter, Temitope Erinfolami, Toyyib Abdulkareem, Yeong Jer Lim, Hanna Renshaw, Brogan Johnston, Hanhua Liu, Tess Nowell, Marianne Moxon, Matthew Wells, Cathy Burton, Nagesh Kalakonda, Mark Bishton, Catrin Tudur Smith, Andrew Pettitt, Pamela McKay

Blood (2025) 146 (Supplement 1): 6298.

https://doi.org/10.1182/blood-2025-6298

Published: 2025

Journal Articles

Analysis of the role of baseline PET/CT in a prospective study of unselected patients: The UK MCL biobank

Georgina Naylor, Sarah Mant, Asha Omar, Lexy Sorrell, Nicola Crosbie, Peninsula Clinical Trials Unit, Kristian Bowles, Safia Dawi, Christopher McNamara, Melanie Oates, Mark Bishton, Toby Eyre, Andrew Pettitt, Simon Rule, David Lewis

Blood (2025) 146 (Supplement 1): 5376.

https://doi.org/10.1182/blood-2025-5376

Published: 2025

Journal Articles

Treatment intensity and region of diagnosis affect survival in primary CNS lymphoma in England: A national cohort study from the uncover project.

Mark Bishton, Nurunnahar Akter, indrani karpha, Sarrah Tayabali, Temitope Erinfolami, Catrin Tudur Smith, Hanhua Liu, Yeong Jer Lim, Brogan Johnston, Jeffery Smith, Kate Cwynarski, David Howarth, Nagesh Kalakonda, Andrew Pettitt, Christopher Fox

Blood (2025) 146 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2025-6325

Published: 2025

Journal Articles

A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank

Sarah Mant, Georgina Naylor, Nicola Crosbie, Sree Aroori, Mark J Bishton, Kristian Bowles, Safia Dawi, Toby A. Eyre, Wendy Ingram, Abigail Martin, Christopher McNamara, Melanie Oates, Andrew Pettitt, Claire Scully, Brian Wainman, Mark Warner, Simon Rule, David John Lewis

Blood (2024) 144 (Supplement 1): 1641.

https://doi.org/10.1182/blood-2024-209701

Published: 2024

Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Blood (2024) 144 (Supplement 1): 585.

https://doi.org/10.1182/blood-2024-211449

Published: 2024

Journal Articles

Deep Immune Profiling Identifies Novel T-Cell Subpopulations That Influence Specific Clinical Outcomes in Chronic Lymphocytic Leukaemia (CLL)

Yeong Jer Lim, Andrew Duckworth, Kim Clarke, Paul Kennedy, Melanie Oates, Matthew Gornall, Nagesh Kalakonda, Joseph Slupsky, Andrew Pettitt

Blood (2023) 142 (Supplement 1): 4626.

https://doi.org/10.1182/blood-2023-185091

Published: 2023

Journal Articles

High Dimensional Detection of Non-Malignant B-Cells and Its Clinical Implications in Patients with Chronic Lymphocytic Leukaemia (CLL) Undergoing Frontline Therapy

Yeong Jer Lim, Andrew Duckworth, Kim Clarke, Melanie Oates, Matthew Gornall, Nagesh Kalakonda, Joseph Slupsky, Andrew Pettitt

Blood (2023) 142 (Supplement 1): 1894.

https://doi.org/10.1182/blood-2023-185018

Published: 2023

Journal Articles

Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL)

Yeong Jer Lim, Andrew Duckworth, Kim Clarke, Melanie Oates, Matthew Gornall, Nagesh Kalakonda, Joseph Slupsky, Andrew Pettitt

Blood (2023) 142 (Supplement 1): 1455.

https://doi.org/10.1182/blood-2023-185063

Published: 2023

Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Blood (2023) 142 (Supplement 1): 631.

https://doi.org/10.1182/blood-2023-178298

Published: 2023

Journal Articles

Telomere Length and DNA Methylation Epitype Both Provide Independent Prognostic Information in CLL Patients; Data from the UK CLL4, Arctic and Admire Clinical Trials

Louise J. Carr, Kevin Norris, Helen Parker, Anna Nilsson-Takeuchi, Dean J. Bryant, Harindra Eranthi Amarasinghe, Latha Kadalayil, Monica Else, Tomasz Wojdacz, Andrew Pettitt, Peter Hillmen, Anna Schuh, Renata Walewska, Duncan M. Baird, David Graham Oscier, Christopher C. Oakes, Jane Gibson, Chris Pepper, Jonathan C. Strefford

Blood (2023) 142 (Supplement 1): 6514.

https://doi.org/10.1182/blood-2023-177575

Published: 2023

Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Blood (2022) 140 (Supplement 1): 231–233.

https://doi.org/10.1182/blood-2022-170463

Published: 2022

Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Blood (2022) 140 (Supplement 1): 222–223.

https://doi.org/10.1182/blood-2022-166700

Published: 2022

Journal Articles

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Blood (2022) 140 (Supplement 1): 2283–2285.

https://doi.org/10.1182/blood-2022-156085

Published: 2022

Journal Articles

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Andy C. Rawstron, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Shanna Maycock, BSc, MSc, Nichola Webster, Kristian Brock, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Francesca Yates, PhD, Rebecca Jarvis, BSc, Surita Dalal, PhD, Ruth M. de Tute, PhD FRCPath, Paul Moss, MBBS, PhD FRCP, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Piers Patten, MD PhD, Christopher Fegan, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, Christopher P. Fox, MD PhD, Adrian Bloor, PhD FRCP, FRCPath, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-136990

Published: 2020

Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-136960

Published: 2020

Journal Articles

Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia

Blood (2019) 134 (Supplement_1): 1740.

https://doi.org/10.1182/blood-2019-122037

Published: 2019

Journal Articles

40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study

Rory McCulloch, FRCPath, MRCP, MBBS, Alexandra Smith, PhD, Brian Wainman, Wendy Ingram, Amelia Lewis, Matthew Hawkins, Nicola Crosbie, Andrew Pettitt, FRCPath, PhD, Simon Rule

Blood (2019) 134 (Supplement_1): 2821.

https://doi.org/10.1182/blood-2019-128340

Published: 2019

Journal Articles

Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma

Rory McCulloch, FRCPath, MRCP, MBBS, Margie Berrow, Brian Wainman, Nicola Crosbie, Andrew Pettitt, FRCPath, PhD, Simon Rule, MD

Blood (2018) 132 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2018-99-114528

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The impact of frailty on real world outcomes for multiple myeloma patients in England – a cohort study from the uncover study group and ukmra frailty group.

Respiratory syncytial virus (RSV) infection in adults with blood cancer: An England-wide population study

Real world epidemiological trends in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), England 2014-2021: Preliminary data from the uncover Study group

Analysis of the role of baseline PET/CT in a prospective study of unselected patients: The UK MCL biobank

Treatment intensity and region of diagnosis affect survival in primary CNS lymphoma in England: A national cohort study from the uncover project.

A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Deep Immune Profiling Identifies Novel T-Cell Subpopulations That Influence Specific Clinical Outcomes in Chronic Lymphocytic Leukaemia (CLL)

High Dimensional Detection of Non-Malignant B-Cells and Its Clinical Implications in Patients with Chronic Lymphocytic Leukaemia (CLL) Undergoing Frontline Therapy

Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL)

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Telomere Length and DNA Methylation Epitype Both Provide Independent Prognostic Information in CLL Patients; Data from the UK CLL4, Arctic and Admire Clinical Trials

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia

40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study

Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only